This research study is looking at the role of a supportive care mobile app in improving symptoms, coping skills, and quality of life in patients with non-small cell lung cancer.
This research study is a Feasibility Study, which is the first-time investigators are examining this supportive care mobile app intervention. The goal of this research study is to refine and examine the feasibility and benefits of a supportive care mobile app to improve symptoms, coping skills, and quality of life in patients with non-small cell lung cancer. Many people diagnosed with lung cancer experience challenging symptoms and increased stress. To help address these concerns, this study is exploring how a mobile application (app) intervention, designed specifically for people with lung cancer, can expand the availability of much needed supportive care services. The research study procedures include: * A supportive care mobile app consisting of six intervention modules that focus on components of wellbeing, such as physical, social, functional, and emotional wellbeing * Questionnaires asking about demographic information (e.g., gender, ethnicity, income) and participants' experience with cancer (e.g., quality of life, symptoms) * Data collection from participants medical records After completing a baseline study questionnaire, participants will be randomized into two (2) study groups: * Usual Care Group: Participants will receive standard oncology care and attend their regular clinic visits. Study staff will monitor participant use of supportive care services. * Intervention Group: Participants will be provided with a study-issued tablet computer to access the mobile app and receive tutorial and instructions for how to use the app. Participants will be in this research study for 12-14 weeks. It is expected that about 120 people will take part in this research study. The sponsors of this study are the National Comprehensive Cancer Network (NCCN) and AstraZeneca Pharmaceuticals. NCCN is a non-profit alliance of leading cancer centers across the United States, and AstraZeneca Pharmaceuticals is a global bio-pharmaceutical company. These two sponsors are together providing funding and oversight for the conduct of this research study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
120
Tablet computer with application providing modules on skills for managing symptoms and coping.
Standard oncology care with monitoring of supportive care services usage
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Mass General/North Shore Cancer Center
Danvers, Massachusetts, United States
Dana-Farber Brigham Cancer Center at Milford Regional Medical Center
Milford, Massachusetts, United States
Study feasibility based on rates of participant recruitment and completion of assigned study procedures
Study feasibility will be defined as ≥ 65% approach-to-enrollment rate of eligible participants and ≥70% completion rate of study procedures (at least four mobile app modules and assigned study questionnaires)
Time frame: 12 weeks
Patient-reported acceptability and usability of the mobile application intervention on the System Usability Scale
Describe patient-reported acceptability and ease of use of the mobile application intervention based on scores from the System Usability Scale (score range: 0-100; higher scores indicate greater acceptability and ease of use)
Time frame: 12 weeks
Compare patient-reported quality of life between study groups on the Functional Assessment of Cancer Therapy-Lung Scale
Compare between study groups patient-reported quality of life based on scores from the Functional Assessment Cancer Therapy-Lung Scale at 12 weeks (score range: 0-136; higher scores indicate better quality of life)
Time frame: 12 weeks
Compare patient-reported symptoms between study groups on the MD Anderson Symptom Inventory
Compare between study groups patient-reported symptom severity and interference based on scores from the MD Anderson Symptom Inventory at 12 weeks (score range: 0-10 on the symptom severity and interference sub-scales; higher scores indicate worse symptoms)
Time frame: 12 weeks
Compare patient-reported psychological distress between study groups on the Hospital Anxiety and Depression Scale
Compare between study groups patient-reported anxiety and depression symptoms based on scores from the Hospital Anxiety and Depression Scale at 12 weeks (score range: 0-21 on the anxiety and depression sub-scales; higher scores indicate worse psychological distress)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Newton-Wellesley Hospital
Newton, Massachusetts, United States
Dana-Farber Brigham Cancer Center at South Shore
South Weymouth, Massachusetts, United States
Time frame: 12 weeks
Compare patient-reported coping between study groups on the Brief COPE Scale
Compare between study groups patient-reported coping strategies based on scores from the Brief COPE Scale at 12 weeks (score range: 2-8 on each of 14 coping sub-scales; higher scores indicate greater use of that specific coping strategy)
Time frame: 12 weeks